EX-99.1 2 ef20048845_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1



ASX Quarterly Results Announcement

Name of entity:
Anteris Technologies Global Corp. (“ATGC”)
ARBN:
677 960 235
Reporting period:
For the quarter ended March 31, 2025
 
The attached Form 10-Q Quarterly Report for the quarter ended March 31, 2025 has been filed with the U.S. Securities and Exchange Commission.  It includes the condensed consolidated financial statements which have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and are denominated in U.S. dollars.
 
The following supplementary information is provided in connection with the Form 10-Q for the purposes of compliance with ASX Listing Rule 4.7C. This information should be read in conjunction with the Form 10-Q and is provided to satisfy the Company’s ongoing disclosure obligations under the ASX Listing Rules.
 
Details of business activities during the quarter
 
Refer to the Form 10-Q and the “Anteris Announces Results for the First Quarter of 2025” announcement lodged with the ASX on May 14, 2025.
 
Use of funds:
 
On December 12, 2024, our registration statement on Form S-1 relating to our initial public offering became effective pursuant to which we issued and sold 14,878,481 shares of Common Stock at a public offering price of US$6.00 per share.
 
We received net proceeds of US$80.0 million, after deducting the underwriting discounts, commissions and offering expenses and giving effect to the exercise of the underwriters’ option to purchase additional shares.  The use of proceeds from our initial public offering, as of March 31, 2025, was as follows:
 
•
US$20.8 million for the ongoing development of DurAVR® THV and the preparation and enrolment of the Pivotal Trial of DurAVR® THV for treating severe aortic stenosis; and
 
•
US$10.5 million for net working capital and other general corporate purposes including the repayment of US$6.4 million of debt including the Obsidian convertible notes and options.
 
Aggregate amount of payments to related parties and their associates:
 
During the first quarter of 2025, the aggregate amount of payments to related parties and their associates (which includes director fees, Company secretarial fees, CEO, President and CFO remuneration) was US$1.77 million.  The quarterly amount includes annual incentive bonuses.  These payments were included in cash flows from operating activities.
 
There were no payments to related parties or their associates included in cash flows from investing activities.


ENDS

About Anteris
 
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris’ lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow.  DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.  The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.

Forward-Looking Statements

This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts, including the objectives of and plans for Anteris’ studies and trials, the timing of the PARADIGM Trial, the goals of the expansion of the global manufacturing capacity and the sourcing of ADAPT® tissue for the DurAVR® THV in the future. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2024 that was filed with the Securities and Exchange Commission and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.

Authorisation and Additional information

This announcement was authorised for release on the ASX by the Board of Directors.

For more information:

Investor Relations Investor Relations (US)
investors@anteristech.com mchatterjee@bplifescience.com
Debbie Ormsby Malini Chatterjee, Ph.D.
Anteris Technologies Global Corp. Blueprint Life Science Group
+61 1300 550 310 | +61 7 3152 3200 +1 917 330 4269
   
Website www.anteristech.com
X       @AnterisTech
LinkedIn https://www.linkedin.com/company/anteristech
1